Cancer Genetics — Merger or Acquisition (January 2021)
15 slides from Cancer Genetics's merger presentation, Jan 8, 2021

Slide 1: Disrupting Drug Discovery
CANCER GENETICS INCORPORATED Company Presentation Q1 2021 Disrupting Drug Discovery Integrating Novel Human Spheroid Biology & Data Science Technologies with IND-Enabling Expertise CHESS StemMonix

Slide 2: Safe Harbor
SAFE HARBOR Additional Information about the Proposed Merger and Where to Find It In connection with the proposed Merger between Cancer Genetics (“CGIX") and Stemonix (the “Merger”), CGIX and Stemonix intend to file relevant materials with the Securities and Exchange Commission, or the SEC, includin

Slide 3: Defining a New Approach
DEFINING A L New Approach lels for predicting drug efficacy DATA SCIENCE capabilities bring human data to the have underperformed EARLIEST stages of the R&D process and OPTIMIZE THERAPEUTIC EFFICACY & SAFETY Stemonix has created HIGHLY FUNCTIONAL HUMAN spheroids (organ-like models) at SCALE Human ne

Slide 4: Strategic Value Proposition
Strategic Value Proposition Human-First Drug Discovery Engine: Discovery Engine Industrialized Human Spheroids (Discovery) Data Science Machine Learning Global Pharma Partners GSIBES no STEMONIX CGIX-vivoPharm Cancer Big Data Tumor Line Library Global Partners Efficacy & Safety Data Late Stage Precl

Slide 5: Value Throughout Preclinical Discovery
Value Throughout Preclinical Discovery From ID to IND Early Discovery Platform Preclin. Studies (ADME-Tox) Target ID & Validation Lead Identification Lead Optimization Human iPSC- Assay Development Target-to-Hit & Screening GLP Studies Spheroids Phenotypic Hit-to-Lead Screening + Efficacy/Toxicity +

Slide 6: Global Reach
Global Reach Minneapolis, MN Spheroid Production New Jersey 8 Munich, Germany ige) - HQ yject Management, we Marketing Hershey, PA San Diego, CA In vivo Testing Drug Discovery Victoria South Australia Safety & Toxicology Analytical CHESS StemMonix

Slide 7: Discovery In Action
Discovery In Action Highly-scalable platform for early discovery, pre-clinical, and pharmacology provides guidance, preparation of samples, and clinical trial design +. CNS, CARDIAC AND ['@p } ONCOLOGY STUDIES 25 & TRIALS* BY THE NUMBERS ** CNS and Cardiac are from StemoniX and Oncology are from viv

Slide 8: Proven Team Led By Passion
Proven Team Led By Passion Jay Roberts, MBA Ping Yeh, MS MBA Robert Petcavich, PhD Chief Executive Officer Chief Innovation Officer Interim Chief Science Officer Cofounder/CEO of StemoniX and nanotechnologist Cofounder/CSO of Stemonix 30+ years healthcare executive leader 30 year experienced Senior

Slide 9: Convergence Of Biology and Computing
Convergence Of Biology and Computing Industrialized Highly-Functional AnalytiX ™ Software Technologies Human Spheroids Data Science, Analytics, ML Prioritize the Most Effective Compounds Rank-ordered Compound Listing Target | Drug | Recovery (%) > Drugs rank-ordered by parameter > Example from recen

Slide 10: Human Disease Models and Capabilities
Human Disease Models and Capabilities Human First Discovery AlAssisted De-risked Platform Assay Phenotypic Lead ” Menor sie aos Bese Model Development | Development | Screening Ce ROnienceton Selection Studies CDKL5 Deficiency Disorder oEach microOrgan Cancer microBrain‘ (GBM/Breast Mets) Neuro-Sphe

Slide 11: Biopharma Relationships
Biopharma Relationships + Large and small molecule drug discovery Partnering with 7 of the Top 10 * Custom model development global biopharma companies + Patient-derived/genetically engineered iPSC lines . . i ina2 4st Neurospheroid' Technology nT) Ue LeeMUe) a Teicha ily Evaluated within the IQ Con

Slide 12: Seeding & Monetizing Partnerships
Seeding & Monetizing Partnerships Representative z ee as Market Deals Single Partner Lifetime Value nts + Royalty Potential) License Out * Clinical assets / models Hemoshear & Takeda (Upfronts + $470M) Leveraged IP { i | 1 * Internal Drug | i i Validate: mEScONEnY Evotec & Celgene gs Manufacture i 6

Slide 13: A Human First Approach
A Human First Approach Benefits of Incorporating Human Insights into Traditional Drug Discovery De-risks Human relevant in vitro screening and in silico investigation allows for forecasting of therapeutic success prior to clinic and results in superior tox & efficacy Optimizes Human disease models m

Slide 14: Transformational Strategy
Transformational Strategy Human-First Drug Stemonix er) Discovery & Development Engine: O .@ i iti Where Scientific * Vertically Integrated > Predictive of Where sient Insights Clinical Success Pw, a pharm partners of Success ¢ Software-accelerated ad Development > faster Bash ito Digital Meets Mark

Slide 15: Stemonix
Stemonix CANCER GENETICS INCORPORATED Investor Contact: ® Jennifer K. Zimmons. Ph.D. Investor Relations Zimmons International Communications, Inc. Email: [email protected] Phone: +1.917.214.3514
Source: SEC EDGAR · 425 filed Jan 8, 2021
More decks from Cancer Genetics Inc
Vyant Bio — Q1 2022 Earnings Presentation14 slides · May 16, 2022
Merger or Acquisition (September 2020)22 slides · Sep 15, 2020
Q2 2018 Earnings Presentation10 slides · Aug 14, 2018
Q1 2018 Earnings Presentation11 slides · May 15, 2018
FY2017 Earnings Presentation12 slides · Apr 2, 2018
Q3 2017 Earnings Presentation13 slides · Nov 9, 2017